Tag:

Henri Termeer

Latest Headlines

Latest Headlines

Ex-Genzyme CEO to serve as Prosensa's strategic adviser

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...

Outgoing Genzyme CEO Termeer hops on to AVEO board

Henri Termeer ( photo ) is leaving the newly acquired Genzyme with a severance deal worth potentially more than $200 million, but he'll be keeping his finger in the biotech game as a new director of

Genzyme's Termeer to pocket up to $221M

Genzyme CEO Henri Termeer, 2010's top biopharma whipping boy, will leave the biotech with at least $158.4 million, according to Bloomberg. Citing regulatory filings, the news service adds that

Sanofi, Genzyme chiefs cite progress in merger talks

Yesterday Sanofi ( $SNY ) CEO Chris Viehbacher ( photo ) got a chance to sound mildly positive about the chances of hashing out a merger pact with Genzyme ( $GENZ ). And today Genzyme CEO Henri Termeer (

Termeer counsels patience on Sanofi bid

Speaking to a Chamber group in Boston yesterday Genzyme's Henri Termeer ( photo ) made it clear that he's going to sit tight until he can hammer out an acceptable offer for the company. "It took us 30

Termeer: "It can't go on forever"

Genzyme's CEO spent a good part of Monday burnishing the prospects of their experimental MS drug alemtuzumab, and thereby the value of the big biotech. With Sanofi so far unwilling to budge from its

Sources: Genzyme ($GENZ) floats $82 bid by Takeda

Anxious to stir up a bidding war, Genzyme ( $GENZ ) has reportedly initiated a discussion with Japan's Takeda around an $82-per-share target offer, according to a number of press reports. Takeda is

Dear Henri: Sanofi chief advises Genzyme against defensive moves

Sanofi-Aventis ( $SNY ) CEO Chris Viehbacher ( photo ) sounds a little miffed that Genzyme's ( $GENZ ) board would be out encouraging new bids for the big biotech without even so much as a lunch date to

Genzyme's Termeer loses millions at $69 per share

Genzyme CEO Henri Termeer ( photo ) may have a selfish reason for refusing Sanofi-Aventis' $69-per-share offer. Yes, Termeer would get a big buyout bonus--$11 million by some estimates--but that bonus

Sanofi-Genzyme takeover bid gets heated

It's been a busy morning with Sanofi-Aventis-Genzyme news. According to news reports, Sanofi is denying suggestions by Genzyme that it privately offered a higher price for the Cambridge, MA-based